Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer-Reference-Cited by-同舟云学术

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer

Published:2019-06 Issue:6 Volume:75 Page:920-926
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Heck Matthias M.,Tauber Robert,Schwaiger Sebastian,Retz Margitta,D’Alessandria Calogero,Maurer Tobias,Gafita Andrei,Wester Hans-Jürgen,Gschwend Jürgen E.,Weber Wolfgang A.,Schwaiger Markus,Knorr Karina,Eiber Matthias

Publisher

Elsevier BV

Subject

Urology

Reference13 articles.

1. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients;Rahbar;J Nucl Med,2017

2. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study;Hofman;Lancet Oncol,2018

3. Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy;Baum;J Nucl Med,2016

4. Systemic radioligand therapy with (177)Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer;Heck;J Urol,2016

5. PSMA targeted radioligand therapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival;Rahbar;Eur J Nucl Med Mol Imaging,2017

Cited by 219 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-03

2. Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy;Nuklearmedizin - NuclearMedicine;2024-09-03

3. Organ and tumor dosimetry including method simplification for [177Lu]Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer;EJNMMI Physics;2024-07-17

4. PSMA-based therapeutics for prostate cancer;Expert Opinion on Pharmacotherapy;2024-07-02

5. Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection;Frontiers in Oncology;2024-06-27